| Bonfils C. et al., AACR 2012 Annual Meeting, April 2012The Combination of MGCD265, a Met/VEGFR Inhibitor in Clinical Development, and Erlotinib Potently Inhibits Tumor Growth by Altering Multiple Pathways Including Glycolysis |  |
| Wheler, J. et al. AACR-NCI-EORTC 2011, November 2011The Determination of the Maximum Tolerated Dose (MTD) of MGCD265 on an Intermittent Schedule: Phase I Study Results (Study 265-102) | |
| Rasco, D. W., et al. ASCO 2011 Annual Meeting, June 2011Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multi-targeted receptor tyrosine kinase inhibitor, in combination with docetaxel | |
| O’Dwyer, Peter et al. ASCO 2011 Annual Meeting, June 2011MGCD265, an oral Met/VEGFR multi-targeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase 1 clinical experience | |
| Bonfils, C. et al. AACR 102nd Annual Meeting, April 2011Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR multi-targeted kinase inhibitor in clinical development, in combination with taxanes | |
| Patnaik, A. et al. 22nd EORTC-NCI-AACR, November 2010MGCD265, an orally active Met/VEGFR multi-targeted kinase inhibitor, in combination with erlotinib : clinical and preclinical experience | |
| O’Dwyer, P. et al. 22nd EORTC-NCI-AACR, November 2010MGCD265, an orally active Met/VEGFR multi-targeted kinase inhibitor, in combination with docetaxel : clinical and preclinical experience | |
| Heath, E. et al., 2010 ASCO Annual Meeting, June 2010A phase I study of oral administration of MGCD265 in patients with advanced malignancies (study 265-102) | |
| Drouin, M. et al., 2010 ASCO Annual Meeting, June 2010Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study (265-101) | |
| Besterman, J. et al., 2010 ASCO Annual Meeting, June 2010Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib | |
| Fournel, M. Et al., 2010 AACR Annual Meeting, April 2010Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multi-targeted kinase inhibitors in phase Ii clinical development, in combination with an EGFR inhibitor | |
| Beaulieu, N. et al. 2010 AACR 101st Annual Meeting, April 2010MGCD265, an orally active Met/VEGFR multi-targeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants | |
| LoRusso, P. et al., 2009 AACR-NCI-EORTC International Conference, November 2009A phase I dose-escalation study of MGCD265 in patients with advanced malignancies (study 265-102) | |
| Kollmannsberger, C.K. et al. 2009 ASCO Annual Meeting, May 2009Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101) | |
| Hong, D. et al. 2009 ASCO Annual Meeting, May 2009Phase I study of MGCD265 administered intermittently to patient s with advanced malignancies (Study 265-102) | |
| Beaulieu, N. et al. 20th EORTC-NCI-AACR Symposium, October 2008Preclinical pharmacodynamic markers of MGCD265, a potent orally active c-Met/VEGFR multi-targeted kinase inhibitor in phase I clinical trials | |
| Besterman, J. 3rd Protein Kinases in Drug Discovery Conference, May 2008MGCD265, a multi-targeted kinase inhibitor | |
| Beaulieu, N. et al. AACR Annual Meeting 2008, April 2008Preclinical development of MGCD265, a potent orally active c-Met/VEGFR multi-target kinase inhibitor | |
| Saavedra, O. et al., Gordon Research Conference, August 2007A new series of Thieno[3,2-b] pyridines, inhibitors of the HGF and VEGF receptor family | |
| Raeppel, S. et al., 43rd International Conference on Medicinal Chemistry, July 2007Inhibitors targeting multiple receptor tyrosine kinases for anticancer therapies | |
| Vaisburg, A. CHI's 5th Annual Protein Kinase Targets Conference, June 2007Thienopyridine-Based Multi-Targeted Kinase Inhibitors | |
| Beaulieu, N., et al. 18th EORTC-NCI-AACR Cancer Symposium, Nov. 7-10, 2006, PragueIdentification and characterization of novel, orally active inhibitors of c-MET and Ron Receptor Tyrosine Kinases | |
| Claridge, S. et al., 232nd ACS National Meeting, Sept 10-14, 2006, San FranciscoNoel Thieno[3,2-b]pyridine Scaffold Based Inhibitors of the c-Met and VEGFR Receptor Family | |
| Nguyen, H. et al, AACR 9th Annual Meeting, April 1-5, 2006, Washington DCEvaluation of Antitumor Activity, Anti-Angiogenic Activity and Pharmacodynamic End Points for Orally Active Multi-Targeted Anti-Angiogenic Kinase Inhibitors Targeting c-MET, Ron, VEGF and Tie-2 Receptors | |
| Beaulieu, N. et al, ACCR-NCI-EORTC, November 14-18, 2005, PhiladelphiaNovel, Orally Active Multi-Kinase Inhibitors of c-MET and the VEGF Receptor Family Exhibit Potent Antiangiogenic Activity and Antitumour Efficacy in Preclinical Models | |